Front. Public Health

Sec. Health Economics

Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1411495

Provisionally accepted

The final, formatted version of the article will be published soon.

You have multiple emails registered with Frontiers:

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

In the context of economic policy uncertainty tends to be normalized, and corporate innovation behavior can cope with the cost shocks caused by economic policy uncertainty. This paper empirically investigates the relationship between economic policy uncertainty and firms' innovation based on relevant data of Chinese A-share pharmaceutical listed companies from 2015-2022 and examines the mechanism effects of financialization, executive compensation, and government subsidies. The results of the study find that economic policy uncertainty significantly increases firms' innovation intensity. Firms with dual-job management, overseas backgrounds, and non-state ownership types increase firms' innovative behavior in the face of economic policy uncertainty.Further analysis shows that economic policy uncertainty increases firms' innovation intensity through three mechanisms: increased financialization of firms, access to government subsidies, and incentives for management. Increasing firms' innovation intensity can cope with risky shocks from economic policy uncertainty, but not with negative shocks that increase costs. Financialized transformation helps firms cope with business risks and late costs associated with economic policy uncertainty.Based on these results, this study provides empirical evidence for the theoretical inference that firms cope with shocks from economic policy uncertainty and thus increase their innovative behavior.

Keywords: economic policy uncertainty, Corporate innovation, financialization, Listed pharmaceutical companies, cost

Received: 03 Apr 2024; Accepted: 21 Nov 2024.

Copyright: © 2024 . This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.